Indomethacin (Indomethacin) Patent Expiration, LOE Window & CMS Spending

Indomethacin (Indomethacin) by Chartwell Molecules: Off-Patent Genericized (AB Competition), 6 AB generics, $6.8M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChartwell Molecules
FDA Application & PathwayN018829 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$6.8M
2024 Medicare Part D Spend$3.6M
2024 Medicaid Spend$3.3M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 93.7% 2-yr change)